Aton Pharma appoints Brazil distributor
Aton Pharma, a US specialty pharmaceutical firm, has signed a distribution agreement with Meizler Biopharma S/A to commercialize Cuprimine (penicillamine) and Syprine (trientine) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory clearance of Syprine.
"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael Wells, chief executive of Aton Pharma, noting that Brazil is the largest pharmaceutical market in Latin America.
"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, the Brazilian firm's president, adding that the two products "both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze